Abstract
Treatment of Chagas disease is a controversial issue because the available drugs are highly toxic. Clomipramine is a tricyclic antidepressant drug that inhibits Trypanosoma cruzi’s trypanothione reductase, provoking the death of the parasite and preventing the cardiac damage when used for the treatment of acutely infected mice. Here, we studied the effectiveness of clomipramine (5 mg/kg/day for one month) as chemotherapy for T. cruzi-infected mice in the chronic indeterminate stage of the infection. The animals were analyzed in the cardiac chronic phase. Survival of treated animals was 84% while for the untreated ones was 40%; most of the animals presented electrocardiographic abnormalities. Affinity and density of cardiac β receptors from infected and treated mice were similar to those in the indeterminate phase, showing that clomipramine treatment stopped the increment of functional alterations provoked by the infection, while untreated mice presented affinity and density significantly diminished. Hearts from infected and untreated mice in the chronic stage presented mononuclear cells, necrosis and fiber dissolution while hearts from treated animals showed only isolated inflammatory infiltrates. Present results demonstrate that clomipramine used in the chronic indeterminate phase of the T. cruzi infection modified the natural evolution of the chagasic cardiopathy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andrade SG, Magalhes JB, Pontes AL (1989) Therapy of the chronic phase of the experimental infection by Trypanosoma cruzi with benznidazole and nifurtimox. Rev Soc Bras Med Trop 22:113–118
Barioglio SR, Lacuara JL, Paglini de Oliva P (1987) Effects of clomipramine upon motility of Trypanosoma cruzi. J Parasitol 73:451–452
Bond CS, Zhang Y, Berriman M, Cunningham ML, Fairlamb AH, Hunter WN (1999) Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. Structure 7:81–89
Bustamante JM, Rivarola HW, Fernandez AR, Enders JE, Fretes R, Palma JA, Paglini-Oliva PA (2003a) Indeterminate Chagas disease: Trypanosoma cruzi strain and reinfections are factors involved in the progression of cardiopathy. Clin Sci 104:415–420
Bustamante JM, Rivarola HW, Fernández AR, Enders JE, Fretes R, d'Oro G, Palma JA, Paglini-Oliva PA (2003b) Trypanosoma cruzi reinfections provoke synergistic effect and cardiac b-adrenergic receptors’ dysfunction in the acute phase of experimental Chagas disease. Exp Parasitol 103:136–142
Bustamante JM, Rivarola HW, Palma JA, Paglini-Oliva P (2004) Electrocardiographic pattern in Trypanosoma cruzi reinfected mice. Parasitology 128:415–419
Coupland N, Wilson S, Nutt D (1997) Antidepressant drugs and the cardiovascular system: a comparison of tricyclics and selective serotonine reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol 11:83–92
Coura JR, Castro SL (2002) A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97:3–24
De Oliveira RB, Vaz ABM, Alves RO, Liarte DB, Donnici CL, Romanha AJ, Zani CL (2006) Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors. Mem Inst Oswaldo Cruz 101:169–173
Díaz de Toranzo EG, Castro JA, Franke de Cazzulo BM, Cazzulo JJ (1988) Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi. Experientia 44:880–881
Enders JE, Paglini P, Fernandez AR, Marco F, Palma JA (1995) Cardiac beta-receptors in experimental Chagas’ disease. Rev Inst Med Trop Sao Paulo 37:59–62
Fabbro D, Arias ED, Streiger M, Del Barco M, Amicone N, Miglietta H (2001) Evaluación de la quimioterapia específica en infectados chagásicos adultos en fase indeterminada con más de 15 años de seguimiento. Rev Fed Argent Cardiol 30:496–503
Fairlamb AH (1992) Metabolism and functions of trypanothione in the kinetoplastida. Annu Rev Microbiol 46:695–729
Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos de Carvalho AC, Ribeiro Dos Santos R, Soares MB (2005) Treatment with benznidazole during the chronic phase of experimental Chagas’ disease decreases cardiac alterations. Antimicrob Agents Chemother 49:1521–1528
Girones N, Cuervo H, Fresno M (2005) Trypanosoma cruzi-induced molecular mimicry and Chagas disease. Curr Trop Microbiol Immunol 296:89–123
Gutierrez-Correa J, Fairlamb AH, Stoppani AO (2001) Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals. Free Radic Res 34:363–378
Hyland KV, Leon JS, Daniels MD, Giafis N, Woods LM, Wang K, Engman DM (2007) Modulation of autoimmunity by treatment of an infectious disease. Infect Immun 75:3641–3650
Kahn MOF (2007) Trypanothione reductase: a viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design. Drug Target Insights 1:129–146
Kierszenbaum F (2005) Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends in Parasitology 21:513–516
Paglini-Oliva P, Fernández AR, Lacuara JL (1987) Pharmacological and contractile response of myocardium of chagasic Albino Swiss mice. Acta Physiol Pharmacol Latinoam 37:395–401
Rassi A, Rassi WC, Little WC (2000) Chagas heart disease. Clin Cardiol 23:883–889
Rivarola HW, Fernández AR, Enders JE, Fretes R, Gea S, Paglini-Oliva P (2001) Effects of clomipramine on Trypanosoma cruzi infection in mice. Trans R Soc Trop Med Hyg 95:529–533
Rivarola HW, Bustamante JM, Lo Presti S, Fernández AR, Enders JE, Gea S, Fretes R, Paglini-Oliva P (2005) Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area. Exp Parasitol 111:80–86
Romanha AJ, Alves RO, Murta SM, Silva JS, Ropert C, Gazzinelli RT (2002) Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis 186:823–828
Schijman AJ, Vigliano CA, Viotti RJ, Burgos JM, Brandariz S, Lococo BE, Leze MI, Armenti HA, Levin MJ (2004) Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic heart disease. Am J Trop Med Hyg 70:210–220
Schmunis GA (2007) Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102:75–85
Segura MA, Molina de Raspi E, Basombrio MA (1994) Reversibility of muscle and heart lesion in chronic Trypanosoma cruzi infected mice after late trypanocidal treatment. Mem Inst Oswaldo Cruz 89:213–216
Sosa Estani S, Segura E (2006) Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr Opin Infect Dis 19:583–587
Viotti R, Vigliano C (2007) Etiological treatment of chronic Chagas disease: neglected evidence by evidence-based medicine. Expert Rev Anti Infect Ther 5:526–717
Acknowledgments
This work was supported by grants from the Secretaría de Ciencia Técnica (SECyT) from Universidad Nacional de Córdoba and from Universidad Nacional de La Rioja. The experiments comply with the current laws of Argentina that are in agreement with the EC Directive 86/609/ECC for animal experiments.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bazán, P.C., Lo Presti, M.S., Rivarola, H.W. et al. Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment. Parasitol Res 103, 663–669 (2008). https://doi.org/10.1007/s00436-008-1029-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-008-1029-x